
Demenz: Wird Aducanumab bald Alzheimerpatienten helfen?
Spektrum,
Demenz: Wird Aducanumab bald Alzheimerpatienten helfen? Aducanumab soll das Gedächtnis von Menschen mit Alzheimer stärken.
Demenz: Wird Aducanumab bald Alzheimerpatienten helfen? Aducanumab soll das Gedächtnis von Menschen mit Alzheimer stärken.
Biogen has an impressive portfolio of assets that it is continuing to work towards developing.
Der monoklonale Antikörper Aducanumab versprach die erste Therapieoption des Morbus Alzheimers im Frühstadium zu werden.
11:30 22.03.19 – Auch wenn die Hoffnung auf eine wirksame Alzheimer-Therapie in naher Zukunft zerschlagen wurde, sind Experten…
Zwei klinische Studien zur Erprobung eines Alzheimer-Medikaments sind wegen fehlender Aussicht auf Erfolg abgebrochen worden.
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United…
Story highlights There are no available treatments for Alzheimer's disease, the sixth leading cause of death in the US…
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United…
The latest study of a drug designed to clear amyloid deposits in the brain raises questions about whether focusing on the plaque…
Finding a cure for neurodegenerative diseases such as Alzheimer's is challenging.
Finding a cure for neurodegenerative diseases such as Alzheimer's is challenging.
Finding a cure for neurodegenerative diseases such as Alzheimer’s is challenging.
中国科学院科技战略咨询研究院战略情报研究所研制的“2016全球最受公众关注的科学成果”,通过计量统计遴选出天文学与天体物理[1]、物理学、化学、地球科学、生命科学这五个学科中受到科技界热切关注的科学成果,及中国研究者参与的每个学科TOP30受公众关注的科学成…
中国科学院科技战略咨询研究院战略情报研究所 中国科学院科技战略咨询研究院战略情报研究所研制的“2016全球最受公众关注的科学成果”,通过计量统计遴选出天文学与天体物理[1]、物理学、化学、地球科学、生命科学这五个学科中受到科技界热切关注的科学成果,及中国研究…
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
A new world of clinical trial data testing is upon us. Older methods to determine a drug's worth are being replaced by more…
Introduction Biogen (NASDAQ: BIIB ) is known primarily for its leading position in treating multiple sclerosis, the most common…
Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are plowing ahead with hundreds of experiments …
Photo: Heidi De Marco, HO Alzheimer's advocates say the number of Americans living witht the disease will explode from the…
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback recently, Alzheimer's researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 per cent failure rate and a recent setback, Alzheimer's researchers are plowing ahead with hundreds of experiments …
By Melissa Bailey, Kaiser Health News Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are…
Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are plowing ahead with hundreds of experiments …
By Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with…
Memory loss is a great fear for people as they age, unfortunately, there haven't been many successes at arresting that loss.
Memory loss is a great fear for people as they age, unfortunately, there haven't been many successes at arresting that loss.
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
R. Scott Turner, Professor of Neurology and Director of the Memory Disorder Center at Georgetown University Hospital, points to…
Dr, a physician at Duke University Health System and coauthor of The Alzheimer's Action Plan, responds to questions sent in…
From the outbreak of Zika virus to advances in Alzheimer's treatment, 2016 has shifted the public debate on health, bringing…
This isn’t about a drug company’s share price. It’s about people’s hopes, fears, and dignity.
Background With diverse revenue streams, Biogen (NASDAQ: BIIB ) is a biotech stock with a certain amount of safety.
Es gibt nur wenige Themen, bei denen sich die politisch sehr unterschiedlichen Kontrahenten Newt Gingrich von den Republikanern…
PLAQUE BUSTER A new Alzheimer’s drug shows early promise in clearing amyloid-beta plaques (illustrated) from the brain.
5. Dezember 2016 Solanezumab, ein vielversprechender Antikörper gegen Beta-Amyloid, enttäuschte bei einer großen randomisierten…
Für den Pharmahersteller ist es ein herber Rückschlag, für die Alzheimer-Forschung eine bittere Pille: Solanezumab, ein Antikörpe…
Illustration by Andy Potts There are not a lot of things that could bring together people as far apart on the US political…
Third quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16% Nusinersen filed with FDA and EMA for spinal…
] Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) today reported third quarter 2016 financial results, including: Total…
Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
Oct 26, 2016 10:59 UTC CAMBRIDGE, Mass.--(Business Wire)--Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016…
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including…
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. ( BIIB ) today reported third quarter 2016 financial results, including: Total…
Biogen Inc. ( NASDAQ: BIIB ) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
Oct. 26, 2016 10:59 UTC Third quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16% Nusinersen filed with FDA…
Photo Dale B. Schenk, a scientist and industry leader whose discoveries opened new paths into research on Alzheimer’s disease…
ROMA. La notizia è di pochi giorni fa: secondo uno studio pubblicato su Nature sarebbe possibile, grazie a un farmaco, l'Aducanum…
Una de cada tres personas sufrirá demencia a lo largo de su vida. La pérdida progresiva de memoria es una de las consecuencias má…
투여 시와 투여 후 54주째에 촬영된 아밀로이드 PET 이미지 샘플을 통해서 아두카누맙(Aducanumab)이 아밀로이드 플라크를 감소시킨다는 사실이 확인되었다.
Der Kampf gegen die Alzheimer-Krankheit hat bis jetzt nur bittere Früchte hervorgebracht.
About 25 million people around the world have Alzheimer’s disease. Unless a cure is found, that number is expected to triple in…
Das neue Alzheimer-Medikament Aducanumab schürt wieder einmal Hoffnung. Erste Experten sprechen von einem Durchbruch.
Weniger Ablagerungen im Gehirn und weniger geistiger Abbau: Eine Studie gibt Alzheimer-Patienten Hoffnung.
The investigational Alzheimer's disease (AD) treatment aducanumab (Biogen Inc) decreases amyloid plaques, as measured by…
While most media reported on a "game-changing" Alzheimer's drug, neurologists knew that publication in Nature of the full…
Человеческие антитела против патогенного белка, вызывающего болезнь Альцгеймера, уничтожают опасные белковые отложения в мозге бо…
There is marked cortical atrophy in Alzheimer's Disease, associated with loss of gyri and sulci in the temporal lobe and…
Trotz intensiver Forschung ist bislang kein einziges Medikament gegen Alzheimer auf dem Markt.
En studie nylig publisert i tidsskriftet Nature viser lovende resultater etter testing av en medisin som skal fjerne plakk i…
kirstypargeter 3D medical background with magnifying glass examining brain 3D medical background with magnifying glass…
Preliminary clinical trials with a small group of patients suggest that aducanumab, a drug being developed by Biogen, may be…
An initial trial of an antibody therapy that targets Alzheimer’s disease has shown promising results and could signal a long-awai…
London, Sep 1 (IANS): Researchers have developed a new antibody that has the potential to completely remove the harmful beta-amyl…
Image copyright Thinkstock محققان در آمریکا امیدوارند به ساخت داروی آلزایمر نزدیک شده باشند.
Los pacientes y los familiares de personas con alzhéimer podrían tener una nueva esperanza a corto plazo.
A new drug known as aducanumab has been shown to reduce brain plaque in Alzheimer's patients.
.. Biogen, a biotechnology company, found an antibody working against development of amyloid plaques in brain of those…
Une petite étude montre qu'un anticorps, l’aducanumab, peut limiter la progression des plaques amyloïdes et ralentir le déclin…
È l’anticorpo monoclonale Aducanumab, che in un piccolo studio ha dimostrato di eliminare le placche e ridurre la progressione…
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
Ciência
Scientists have developed an antibody that can completely clear the harmful plaques linked to Alzheimer's, as well as slow…
"A revolutionary drug that could stop people from ever developing Alzheimer's disease has been unveiled," the Daily Mail reports.
"A revolutionary drug that could stop people from ever developing Alzheimer's disease has been unveiled," the Daily Mail reports.
The Daily Extra, Company News Published on Thursday, September 1, 2016 FDA granted Fast Track designation to Biogen Inc.
In what some experts are hailing as a major breakthrough in the field of Alzheimer’s research, a new investigational drug was…
Un nouvel espoir pour les personnes atteintes de la maladie d’Alzheimer apparaît enfin dans les résultats d’une étude clinique…
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation Company Also Provides…
The Daily Extra, Company News Published on Thursday, September 1, 2016 FDA granted Fast Track designation to Biogen Inc.